Abbott Laboratories logo

Abbott Laboratories (ABT)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
104. 88
+0.2
+0.1911%
$
181.48B Market Cap
36.49 P/E Ratio
0.28% Div Yield
7.95M Volume
4.44 Eps
$ 104.68
Previous Close
Add Transaction
Day Range
104.19 105.88
Year Range
81.97 132.03
Want to track ABT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Abbott (ABT) Stock Sinks As Market Gains: Here's Why

Abbott (ABT) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Abbott (ABT) settling at $124.64, representing a -1.02% change from its previous close.

Zacks | 9 months ago
Abbott: Not Cheap, But Built To Compound In Uncertain Markets

Abbott: Not Cheap, But Built To Compound In Uncertain Markets

Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Libre), are driving over 12% segment growth, with Diabetes Care revenues surpassing $2B and growing 17%. ABT reaffirmed 2025 organic growth guidance of 7.5%–8% and EPS of $5.12–$5.18, with consistent, low-volatility earnings growth expected through 2027.

Seekingalpha | 9 months ago
Abbott (ABT) Rises Higher Than Market: Key Facts

Abbott (ABT) Rises Higher Than Market: Key Facts

In the latest trading session, Abbott (ABT) closed at $126.45, marking a +1.82% move from the previous day.

Zacks | 9 months ago
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 9 months ago
Abbott Stock May Benefit Following Volt PFA's FDA Approval

Abbott Stock May Benefit Following Volt PFA's FDA Approval

ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance.

Zacks | 9 months ago
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?

Is Trending Stock Abbott Laboratories (ABT) a Buy Now?

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 10 months ago
Why the Market Dipped But Abbott (ABT) Gained Today

Why the Market Dipped But Abbott (ABT) Gained Today

The latest trading day saw Abbott (ABT) settling at $128.47, representing a +2.4% change from its previous close.

Zacks | 10 months ago
Abbott Gains From Lingo CGM's Expansion on Android Platform

Abbott Gains From Lingo CGM's Expansion on Android Platform

ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.

Zacks | 10 months ago
Start the New Year Off With Passive Income: 3 Dividend Kings to Buy Now

Start the New Year Off With Passive Income: 3 Dividend Kings to Buy Now

Dividend stocks may boost your portfolio during any market environment. These particular companies have shown their commitment to dividend payments and growth over time.

Fool | 10 months ago
Here's Why Abbott (ABT) Fell More Than Broader Market

Here's Why Abbott (ABT) Fell More Than Broader Market

In the latest trading session, Abbott (ABT) closed at $122.09, marking a -2.39% move from the previous day.

Zacks | 10 months ago
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Zacks | 10 months ago
Abbott issues US device correction for some glucose monitors over faulty readings risk

Abbott issues US device correction for some glucose monitors over faulty readings risk

Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some units may report falsely low glucose readings.

Reuters | 10 months ago
Loading...
Load More